Monsanto's Roundup ruling causes Bayer share drop

13 August 2018
medical_legal_law_big

Shares in the German life sciences giant Bayer (BAYN: DE) fell by 11% over the weekend after a US court ruled that the weedkiller Roundup (glyphosate) was responsible for the cancer of a school janitor.

A California court ruled that Monsanto, now a unit of Bayer, would be required to pay $289 million in damages to Dewayne Johnson. Mr Johnson reported an accident in 2012 where he was soaked with Roundup, and was diagnosed with non-Hodgkin's lymphoma just two years later. The trial was expedited due to Mr Johnson's limited life expectancy.

Some 5,000 similar lawsuits are believed to be on the horizon, which could cost the German company billions in damages. Bayer completed the purchase of Monsanto in June for $66 billion, but will likely face difficulty integrating the seed and agritech firm into its operations while allegations of misconduct and duplicity swirl around the new subsidiary, which has been accused of hiding Roundup's alleged dangers. The jury accused Monsanto of "malice," and Mr Johnson's lawyer demanded a "day of reckoning" for the firm.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical